Search | Page 17 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep

    ... hematologic malignancies not curable by conventional chemotherapy . Responses to conventional treatment range from zero to 30% ... lymphoma, Hodgkin lymphoma and multiple myeloma with chemotherapy sensitive disease who are ineligible for an autologous transplant. ...

    Clinical Trial last updated 04/29/2016 - 10:06am.

  2. What is Secondary MDS? Everything You Need to Know

    ... who have been previously treated for cancer with chemotherapy or radiation therapy. During this recorded program on May ...

    LMS Item last updated 06/10/2016 - 1:24pm.

  3. MDS Progression to AML: What Patients Need to Know

    ... myeloid leukemia (AML), which does not respond well to chemotherapy . AML is a bone marrow malignancy where the marrow is ...

    LMS Item last updated 06/10/2016 - 1:24pm.

  4. MDS Progression to AML: What Patients Need to Know

    ... myeloid leukemia (AML), which does not respond well to chemotherapy . AML is a bone marrow malignancy where the marrow is ...

    LMS Item last updated 06/10/2016 - 1:24pm.

  5. What is Secondary MDS? Everything You Need to Know

    ... who have been previously treated for cancer with chemotherapy or radiation therapy. In this webinar, Dr. Walker ...

    LMS Item last updated 06/10/2016 - 1:24pm.

  6. Risk of developing MDS and AML after radiation treatment for breast cancer

    ... increases in patients who receive multiple rounds of chemotherapy and radiation therapy, and also in those who undergo stem cell ... lymphoma. Read more about t-MDS Radiation and chemotherapy are key components of cancer treatments and carry an increased ...

    Research Review last updated 05/02/2016 - 9:32am.

  7. A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 Mutation (AML)

    ... FLT3+ AML and not eligible for standard induction chemotherapy or FLT3+ high-risk MDS/CMML (defined as ≥ 10% ... to prior therapy At least 4 weeks beyond the last chemotherapy, (or ≥ 2 weeks or ≥ 2 5 half- lives for targeted agents, ...

    Clinical Trial last updated 05/09/2016 - 4:09pm.

  8. Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies

    ... therapies At least 3 weeks beyond the last chemotherapy , targeted anticancer agent, major surgery or experimental ...

    Clinical Trial last updated 06/06/2016 - 10:47am.

  9. Lenalidomide and Rituximab in Subjects With Previously Untreated Indolent Non-Hodgkin's Lymphoma

    ... is effective as a single agent and in combination with chemotherapy for indolent Non-Hodgkin's Lymphoma. The purpose of this ...

    Clinical Trial last updated 06/06/2016 - 10:17am.

  10. Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid Leukemia or Myelodysplastic Syndrome

    ... multiple mechanisms. Panobinostat belongs to a class of chemotherapy drugs called "histone deacetylase (HDAC) inhibitors." HDAC ... causes them to die. Fludarabine and cytarabine are chemotherapy drugs that are commonly used to treat pediatric patients with ...

    Clinical Trial last updated 04/29/2016 - 10:11am.